[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100615218":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":11,"locations":11,"responsibleParty":26,"collaborators":11,"id":28,"slug":29,"hasResults":30,"nctId":31,"briefTitle":32,"officialTitle":33,"acronym":11,"eligibilityCriteria":34,"healthyVolunteers":30,"sex":35,"minAge":36,"maxAge":37,"enrollmentInfo":38,"targetDuration":11,"studyType":41,"phases":42,"briefSummary":44,"conditions":45,"keywords":48,"overallStatus":49,"whyStopped":11,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":11},{"fullName":5,"class":6},"The Fourth Affiliated Hospital of Zhejiang University School of Medicine","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"alogliptin and actoplus met","EXPERIMENTAL",null,[13],"Drug: alogliptin and actoplus met",{"label":15,"type":16,"description":11,"interventionNames":17},"actoplus met","ACTIVE_COMPARATOR",[18],"Drug: actoplus met",[20,24],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","combination of alogliptin and actoplus met",[9],{"type":21,"name":15,"description":15,"armGroupLabels":25,"otherNames":11},[15],{"type":27,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100615218","phase-4-the-effect-of-alogliptin-combined-with-actoplus-met-on-glucose-and-lipid-metabolism-and-pancreatic-function-in-patients-with-t2dm-complicated-with-mafld-100615218",false,"NCT07289750","The Effect of Alogliptin Combined With Actoplus Met on Glucose and Lipid Metabolism and Pancreatic Function in Patients With T2DM Complicated With MAFLD","The Effect of Alogliptin Combined With Pioglitazone and Metformin Hydrochloride Tablets on Glucose and Lipid Metabolism and Islet Function in Patients With Type 2 Diabetes Mellitus Complicated With Metabolic Dysfunction-associated Fatty Liver Disease","Inclusion Criteria:\n\n* Clinical diagnosis of T2DM\n* Clinical diagnosis of MAFLD\n* HbA1c: 6.5-9.5%\n* BMI: 19-35 kg\u002Fm2\n* No hypoglycemic drugs or insulin have been used within half a year\n\nExclusion Criteria:\n\n* Severe infections, surgeries and other emergency\n* Other types of diabetes\n* Severe cardiovascular, brain, liver and kidney disorders\n* Malignant tumor","ALL","18 Years","75 Years",{"count":39,"type":40},80,"ESTIMATED","INTERVENTIONAL",[43],"PHASE4","To compare the efficacy and safety of the combination of alogliptin and actoplus met with that of actoplus met alone in improving the glucose and lipid metabolism and pancreatic function in T2DM patients complicated with MAFLD.",[46,47],"T2DM","MAFLD",[46,47],"NOT_YET_RECRUITING","2026-03-20",{"date":52,"type":53},"2026-03-24","ACTUAL",{"date":55,"type":40},"2026-05-01",{"date":57,"type":40},"2027-08-31",{"name":5,"class":6}]